SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($2.68), $0.13 worse than the analyst estimate of ($2.55). Revenue for the quarter came in at $2.47 million versus the consensus estimate of $2.92 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.